Aurobindo Pharma Subsidiary Unit Receives US FDA Warning Letter; Impact on Revenue Declared at 2%
Aurobindo Pharma Limited has reported that its subsidiary, Eugia Pharma Specialities Ltd., received a Warning Letter from the U.S. Food and Drug Administration (US FDA). This follows previous regulatory action against the company's formulation manufacturing facility.The facility in question, Unit-I of Eugia Pharma Specialities Ltd., is a wholly owned unit of Aurobindo. The Warning Letter was issued after the unit had previously received Official Action Indicated (OAI) status from the US FDA.
According to the company’s statement, Unit I contributes approximately 2% to the Group's overall revenue. Management has assured stakeholders that there is currently no impact on existing supplies destined for U.S. markets.
Aurobindo Pharma stated that it remains committed to working closely with the US FDA and continues efforts to enhance compliance within the facility. The company confirmed that it will keep stock exchanges updated regarding any future developments concerning the matter.
AUROPHARMA Stock Price Movement
Shares of Aurobindo Pharma Limited are shedding 0.60% in live trading as of 9:47 AM, with the equity moving down to ₹1653.5. The stock is currently navigating within an intraday range of ₹1650 to ₹1670 amid a volume of 133,551 shares traded so far.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.